Short-term Outcomes of Ranibizumab Biosimilars for Secondary Choroidal Neovascularization Associated with Central Serous Chorioretinopathy: A Retrospective Case Series

Purpose: To evaluate the short-term outcomes of ranibizumab biosimilar therapy in patients with secondary choroidal neovascularization (CNV) associated with central serous chorioretinopathy (CSC).Methods: We retrospectively reviewed medical records of CSC patients who developed secondary CNV and were treated with ranibizumab biosimilars, either CKD-701 or SB11.Central retinal thickness (CRT) and uncorrected visual acuity (UCVA) were compared before treatment, at the first follow-up, and at the 6-month follow-up.The presence of subretinal fluid (SRF) and intraretinal fluid (IRF) was also assessed at these time points.Results: Eleven eyes were included in the study, of which 7 were treated with CKD-701 and 4 with SB11.Mean CRT decreased from 361.5 ± 59.2 µm at baseline to 286.3 ± 69.1 µm at the first follow-up and 308.8 ± 67.5 µm at the 6-month follow-up.CRT showed an overall significant difference among the three time points; however, in pairwise comparisons, the reduction was significant at the first follow-up but not at 6 months after Bonferroni correction.Mean UCVA changed from 0.59 ± 0.31 at baseline to 0.54 ± 0.30 at the first follow-up and 0.53 ± 0.31 at 6 months, without statistically significant differences across the three time points.The proportion of eyes with SRF was 100% at baseline, 54.5% at the first follow-up, and 63.6% at 6 months, while IRF was observed in 9.1%, 9.1%, and 0% of eyes, respectively.Conclusions: Ranibizumab biosimilar therapy was associated with a short-term reduction in CRT and partial improvement of exudative changes in some eyes with CSC-associated secondary CNV.